Unknown

Dataset Information

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.


ABSTRACT:

Objective

To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment.

Methods

Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1 and DISCOVER-2 studies. Serum levels of acute phase reactants C reactive protein (CRP) and serum amyloid A (SAA) and inflammatory cytokines/chemokines were measured at weeks 0, 4 and 24 in 300 study participants and 34 healthy controls (HCs). The PSUMMIT studies measured serum interleukin (IL)-17A, IL-17F and CRP after ustekinumab treatment and levels with ustekinumab versus guselkumab treatment were compared.

Results

Baseline serum levels of CRP, SAA, IL-6, IL-17A and IL-17F were elevated in participants with active PsA vs HCs (p<0.05, geometric

SUBMITTER: Sweet K 

PROVIDER: S-EPMC8137258 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature